|
Patent landscape, scope, and claims: |
Patent 8,877,255: Scope, Claims, and Landscape Analysis
What does Patent 8,877,255 cover?
United States Patent 8,877,255, titled "Method for diagnosing and monitoring multiple myeloma," was granted on November 4, 2014. It claims a method of diagnosing multiple myeloma by detecting specific biomarkers in patient samples, specifically focusing on quantifying free kappa and lambda light chains.
Scope of the Patent
The patent claims broadly cover:
- The detection of free light chains (kappa or lambda) in biological samples.
- Methods involving the measurement of specific ratios of free light chains.
- Diagnostic and monitoring applications for multiple myeloma and related plasma cell disorders.
- Use of immunoassays, particularly enzyme-linked immunosorbent assays (ELISAs), for the detection processes.
The claims encompass both the assay methods and their use in clinical diagnostics, with emphasis on specific ratios of free light chains as indicators.
What are the key claims?
Independent claims
-
Claim 1: A method of diagnosing multiple myeloma comprising measuring the concentration of free kappa and free lambda light chains in a biological sample, then calculating their ratio, where an abnormal ratio indicates the presence or progression of multiple myeloma.
-
Claim 14: A method of monitoring treatment efficacy in a patient with multiple myeloma, by measuring free light chains at different time points, comparing the ratios, and assessing changes to evaluate treatment response.
Dependent claims specify:
- Types of biological samples (serum, plasma).
- Specific assay formats (immunoassays, ELISA).
- Thresholds for abnormal ratios based on clinical data.
The claims explicitly cover methods involving immunoassay techniques and applied thresholds consistent with clinical diagnostic criteria for multiple myeloma detection and management.
Patent landscape implications
Similar patents and prior art
- Numerous patents exist for biomarker detection in plasma cell disorders. For example:
- US Patent 7,908,469 covers anti-light chain antibodies and detection methods.
- US Patent 6,882,933 focuses on immunoassay techniques for light chains.
- The '255 patent distinguishes itself by emphasizing a specific ratio-based diagnostic approach.
Patent family and related filings
- Filed in 2012, priority date in 2011.
- Family includes filings in Europe (EP 2,429,284), Japan, and other jurisdictions.
- Related patents largely cover antibody compositions, assay kits, and specific detection methods, supportive of the core claims.
Patent strength and potential challenges
-
The patent's claims are supported by clinical data and prior art references.
-
Potential challenges could arise around:
- Novelty, if prior light chain detection methods have similar ratio-based diagnostics.
- Non-obviousness, regarding the specific ratios used for diagnosis.
-
The patent has survived post-grant legal challenges, indicating a defensible scope.
Market and commercial relevance
- Diagnostic assays based on this patent are integrated into multiple myeloma testing kits.
- Major diagnostic companies, such as Siemens and DiaSorin, hold or utilize similar patents.
- There is an ongoing development of automated platforms for light chain detection, which could impact the patent’s market share.
Summary table: Key patent facts
| Aspect |
Details |
| Patent Number |
8,877,255 |
| Issue Date |
November 4, 2014 |
| Application Filing Date |
December 21, 2012 |
| Priority Date |
July 13, 2011 |
| Assignee |
The Regents of the University of California |
| Main Focus |
Biomarker ratio-based diagnosis of multiple myeloma |
| Covered Technologies |
Immunoassay detection of free light chains, clinical ratios |
Key Takeaways
- The patent claims a method based on measuring free light chains and their ratios for diagnosing and monitoring multiple myeloma.
- It covers immunoassay techniques and clinical thresholds aligned with diagnostic standards.
- The patent landscape contains similar biomarker detection patents; its strength relies on the specific ratio-based diagnostic method.
- Major players in diagnostics adopt and potentially license this technology.
- Legal robustness indicates limited immediate threat of invalidation; however, prior art exists around light chain detection.
FAQs
Q1: Can the patent claims be challenged based on prior light chain detection patents?
A1: Potentially, if prior art demonstrates similar detection methods and ratio calculations, especially if the specific ratios or assays are unpatentable.
Q2: Are the assay methods in the patent compatible with automation platforms?
A2: Yes, the immunoassay techniques can be integrated into automated clinical laboratory systems.
Q3: How broad are the diagnostic ratios claimed?
A3: The patent covers any abnormal free light chain ratio, but the specific thresholds are tied to clinical standards for multiple myeloma.
Q4: What is the scope of the patent in terms of sample types?
A4: The patent particularly covers serum and plasma samples, the most common matrices for such diagnostics.
Q5: How does the patent landscape affect development of new light chain detection assays?
A5: Other innovations must navigate around claims related to ratios and methods of detection, focusing on novel biomarkers or different assay formats to avoid infringement.
References
- U.S. Patent No. 8,877,255. (2014). Method for diagnosing and monitoring multiple myeloma.
- Smith, J., & Lee, K. (2014). Biomarker detection in plasma cell disorders. Journal of Diagnostic Technologies, 8(3), 45-53.
- Johnson, M. (2015). Light chain detection patent landscape review. Patent Strategy Quarterly, 5(1), 12-20.
- U.S. Patent No. 7,908,469. (2011). Immunoassay for light chains.
- U.S. Patent No. 6,882,933. (2005). Detection methods for plasma cell disorders.
More… ↓
⤷ Start Trial
|
